Literature DB >> 26519943

Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.

Jia-Wu Zhu1,2, Feng-Liang Liu1, Dan Mu1,2, De-Yao Deng3, Yong-Tang Zheng1,2.   

Abstract

Host restriction factors and type I interferon are important in limiting HIV and HCV infections, yet the role of HIV, HCV mono- and co-infection in regulating these antiviral genes expression is not clear. In this study, we measured the levels of TRIM5α, TRIM22, APOBEC3G, and IFN-α, -β mRNA expression in peripheral blood mononuclear cells of 43 HIV mono-infected, 70 HCV mono-infected and 64 HIV/HCV co-infected patients along with 98 healthy controls. We also quantified HIV and HCV viral loads in mono- and co-infected patients. The results showed that HCV, HIV mono- and co-infection differentially increased TRIM22, APOBEC3G, and IFN-α, -β mRNA expression while the mRNA expression of TRIMα was upregulated only by HCV-mono infection. HIV/HCV co-infection was associated with higher viral load, compared to either HIV or HCV mono-infection. Additionally, we showed TRIMα and TRIM22 positively correlated with IFN-α, -β, which could be dysregulated by HIV, HCV mono- and co-infection. Furthermore, we found TRIM22 negatively correlated with HCV viral load in mono-infected patients and APOBEC3G positively correlated with HCV viral load in co-infected patients. Collectively, our findings suggest the potential role of restriction factors in restricting HIV, HCV mono- and co-infection in vivo, which appears to be a therapeutic target for potential drug discovery.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  HCV; HIV; co-infection; restriction factors; type I interferon

Mesh:

Substances:

Year:  2015        PMID: 26519943     DOI: 10.1002/jmv.24419

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis.

Authors:  Stephanie M Dillon; Kejun Guo; Gregory L Austin; Sara Gianella; Phillip A Engen; Ece A Mutlu; John Losurdo; Garth Swanson; Prachi Chakradeo; Ali Keshavarzian; Alan L Landay; Mario L Santiago; Cara C Wilson
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

Review 2.  Effect of Opioid Use on Immune Activation and HIV Persistence on ART.

Authors:  Livio Azzoni; David Metzger; Luis J Montaner
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-25       Impact factor: 7.285

3.  Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.

Authors:  Luz M Medrano; Norma Rallón; Juan Berenguer; María A Jiménez-Sousa; Vicente Soriano; Teresa Aldámiz-Echevarria; Amanda Fernández-Rodríguez; Marcial García; Francisco Tejerina; Isidoro Martínez; José M Benito; Salvador Resino
Journal:  J Transl Med       Date:  2016-09-02       Impact factor: 5.531

4.  On the relationship between tripartite motif-containing 22 single-nucleotide polymorphisms and COVID-19 infection severity.

Authors:  Nidhal Raheem Juhi Al-Kaabi; Sepideh Chodari Khameneh; Mohadeseh Montazeri; Mahsa Mardasi; Jalal Mosayebi Amroabadi; Fatemeh Sakhaee; Abolfazl Fateh
Journal:  Hum Genomics       Date:  2022-08-26       Impact factor: 6.481

5.  Anti-HIV Activities and Mechanism of 12-O-Tricosanoylphorbol-20-acetate, a Novel Phorbol Ester from Ostodes katharinae.

Authors:  Huan Chen; Rong Zhang; Rong-Hua Luo; Liu-Meng Yang; Rui-Rui Wang; Xiao-Jiang Hao; Yong-Tang Zheng
Journal:  Molecules       Date:  2017-09-08       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.